A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2016 Planned number of patients changed from 100 to 200 as per ClinicalTrials.gov record.